Prostate cancer trials in Italy

In Italy 119 Also abroad 1481

119 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Where
Milan, Misterbianco, Naples, Negrar, Reggio Emilia, Rozzano
Age
18 years and over
People
670 worldwide
Run by
AstraZeneca
See details and how to joinNCT07611110
No phaseTaking people
PSMA-Guided Surgery and Tissue-Resident T-Cell Profiling in Node-Positive Prostate Cancer
Where
Milan
Age
18 years to 85 years
People
12
Run by
Niguarda Hospital
See details and how to joinNCT07879820
Phase 3Taking people
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Where
Candiolo, Foggia, Genoa, Lecce, Meldola, Milan, Pisa, Rozzano, Verona
Age
18 years and over
People
736 worldwide
Run by
BioNTech SE
See details and how to joinNCT07365995 · EU 2025-524445-27-00
Phase 1/2Taking people
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Where
Cona, Milan, Naples
Age
18 years and over
People
123 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07226986 · EU 2025-521859-23-00
Phase 3Taking people
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Where
Bari, Genoa, Padova, Rozzano
Age
18 years and over
People
1,330 worldwide
Run by
AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00
No phaseNot yet taking people in Italy
Artificial Intelligence Software (Prostate Intelligence) for Detecting Clinically Significant Prostate Cancer on MRI
Where
Rome
Age
18 years and over
People
226
Run by
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT07875491
Phase 3Taking people
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Where
Arezzo, Bari, Bergamo, Chieti, Genoa, Milan, Naples, Palermo, Pisa, Rome, Rozzano, Turin, Varese, Verona
Age
18 years and over
People
700 worldwide
Run by
AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00
Phase 3Taking people
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Where
Bologna, Meldola, Milan, Novara, Orbassano, Padova, Ravenna, Rome, Rozzano, Trento, Verona
Age
18 years and over
People
1,000 worldwide
Run by
Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00
Phase 1/2Taking people
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Where
Bergamo, Meldola, Milan, Roma
Age
18 years to 99 years
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT07590934
Phase 1/2Taking people
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Where
Brescia, Milan, Naples, Orbassano, Rome
Age
18 years and over
People
360 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00
Phase 1/2Taking people
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Where
Milan, Orbassano, Padova
Age
18 years and over
People
188 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07206056 · EU 2025-521880-10-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Candiolo, Milan, Naples, Rome, Rozzano
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Ancona, Bologna, Florence, Milan, Naples, Ravenna
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 1/2Taking people
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Where
Cremona, Rozzano, Verona
Age
18 years and over
People
181 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07190300 · EU 2025-521873-15-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Milan, Naples
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 1Taking people
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Where
Milan, Naples
Age
18 years to 100 years
People
116 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00
Phase 1Taking people
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Where
Candiolo, Rozzano
Age
18 years and over
People
540 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT05983432
Phase 3Taking people
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Where
Foggia, Milan, Modena, Orbassano, Peschiera del Garda, Rozzano, Trento
Age
18 years and over
People
297 worldwide
Run by
Amgen Inc.
See details and how to join2025-520555-89-00 · EU 2025-520555-89-00
Phase 1Not yet taking people in Italy
Clinical study to evaluate the safety and efficacy of a new targeted radioactive drug treatment for advanced prostate cancer
Where
Milan
Age
18 years and over
People
5
Run by
Fondazione IRCCS Istituto Nazionale Dei Tumori
See details and how to join2026-525244-14-00 · EU 2026-525244-14-00
No phaseTaking people
Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration
Where
Milan
Age
18 years and over
People
125
Run by
European Institute of Oncology
See details and how to joinNCT06762379
Phase 3Not yet taking people in Italy
64CuCl2 PET/CT VS 18F-choline PET/CT in prostate cancer
Where
Genoa, Rome
Age
18 years and over
People
285
Run by
A.C.O.M. Advanced Center Oncology Macerata S.r.l.
See details and how to join2025-520861-29-00 · EU 2025-520861-29-00
Phase 2Taking people
Fully hybrid 18F-PSMA PET/MRI as one-stop approach for the diagnosis of clinically significant prostate cancer
Where
Milan
Age
18 years and over
People
167
Run by
Ospedale San Raffaele S.r.l.
See details and how to join2024-512859-21-00 · EU 2024-512859-21-00
Phase 3Taking people
[18F]PSMA-1007 PET CT in patients with newly-diagnosed prostate cancer
Where
Meldola, Negrar
Age
18 years and over
People
355 worldwide
Run by
Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH
See details and how to join2023-504026-19-01 · EU 2023-504026-19-01
Phase 2Taking people
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Where
Milan, Modena, Naples, Rome, Rozzano, Trento
Age
18 years and over
People
218 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07005154 · EU 2024-517653-27-00
Phase 1/2Taking people
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
Where
Rome, Rozzano
Age
18 years and over
People
52 worldwide
Run by
AstraZeneca
See details and how to joinNCT07192614 · EU 2025-520626-37-00